News
GlobalData on MSN7h
Merck announces EC approval of Ogsiveo for desmoid tumours
The oral gamma secretase inhibitor is approved as a single agent for adults with progressing desmoid tumours requiring ...
The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...
Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...
DPA International on MSN22h
Germany's Merck receives approval for cancer drug after takeover deal
The European Commission has granted German pharmaceutical giant Merck approval to use the cancer drug Ogsiveo, the ...
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...
Six digital health technologies (DHTs) that can help with the rehabilitation of people with cardiovascular disease have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback